Company Announcement / Press release Archives - Page 2 of 16

Important information to holders of warrants series TO5: The subscription period is ongoing

Holders of Xspray's warrants series TO5 can, during the period 16-30 November, subscribe for new shares in Xspray Pharma for a price of SEK 40. The warrants were issued in connection with the rights issue in June 2023. The proceeds from subscribed warrants will be used for the launch of Xspray's first product Dasynoc in […]

Xspray Pharma’s large shareholders and key individuals declare their intent to exercise TO5 warrants in November

Xspray Pharma has received written declarations of intent whereby owners of 53 percent of shares in the company state their intent to exercise warrants TO5 to subscribe for newly issued shares corresponding to their holdings of warrants of series TO5 during the subscription period 16-30 November 2023 for the subscription price 40.00 SEK per share. […]

Interim Report Third Quarter 2023

July-September 2023, Group Net sales amounted to SEK 0 thousand (0) Loss before tax amounted to SEK -38,942 thousand (-28,651) Earnings per share before dilution amounted to SEK -1.59 (-1.39) Cash flow from operating activities amounted to SEK -68,611 thousand (-23,091) Cash flow from investing activities amounted to SEK -14,470 thousand (-29,126) January-September 2023, Group […]

Xspray Publication Demonstrates High Concomitant PPI and TKI Use in CML Resulting in Risk of Increased Mortality Which May be Mitigated by DASYNOC™

Xspray Publication Demonstrates High Concomitant Proton Pump Inhibitor and Tyrosine Kinase inhibitor Use in Chronic Myeloid Leukemia Resulting in Risk of Increased Mortality Which May be Mitigated by DASYNOC™. Nearly half of all chronic myeloid leukemia (CML) patients receiving tyrosine kinase inhibitor (TKI) treatment also receive contraindicated proton pump inhibitors (PPI) Risk of death was […]

Xspray Pharma’s Nomination Committee for the Annual General Meeting 2024

Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) publishes the Nomination Committee’s composition for the Annual General Meeting in 2024. The Nomination Committee, which has been appointed in accordance with the principles adopted by the Annual General Meeting on 16 May 2023, consists of: Thomas Eldered, appointed by Flerie Invest AB Gillis Cullin, appointed by Östersjöstiftelsen Johan […]

Xspray Pharma appoints Chief Commercial Officer to drive upcoming Dasynoc™ US product commercialization

Xspray Pharma is pleased to announce the appointment of Edward P. Jordan as Chief Commercial Officer. Mr. Jordan will lead the US product launch and commercialization of Dasynoc™, the company’s leading product, with an anticipated launch in September 2024, subject to FDA approval. This milestone appointment follows Xspray Pharma’s recent settlement of its patent litigation […]

Xspray Pharma and Bristol Myers Squibb Reach Settlement on Dasynoc™ Patent Litigation, Paving Way for Early Market Launch

Xspray Pharma today announced a resolution to its patent litigation with Bristol Myers Squibb (BMS) concerning its product, Dasynoc™. The settlement clears all pending claims, paving the way for Xspray to introduce Dasynoc™ to the market on September 1, 2024, pending final FDA approval. The launch may occur earlier under certain circumstances. The contested patents […]

Interim Report Second Quarter 2023

April-June 2023, Group Net sales amounted to SEK 0 thousand (0) Loss before tax amounted to SEK -51,402 thousand (-28,865) Earnings per share before dilution amounted to SEK -2.27 (-1.40) Cash flow from operating activities amounted to SEK -56,503 thousand (-24,472) Cash flow from investing activities amounted to SEK -16,027 thousand (-29,197) January-June 2023, Group […]

New number of shares and votes in Xspray Pharma

Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) announces today that the number of shares and votes in Xspray Pharma AB has changed as a result of shares being registered due to the rights issue which was carried out in June 2023. Through the rights issue, carried out in June 2023, the number of outstanding shares and […]

Xspray Pharma receives request for additional information concerning Dasynoc from FDA

Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY) announces an update on recent developments regarding the company’s first product, Dasynoc, currently under review by the United States Food & Drug Administration (“FDA”). The company has received a Complete Response Letter (“CRL”) whereby the FDA request additional information particularly regarding additional information to doctors and users related […]